GLOBAL X ETFs ICAV

(an umbrella fund with segregated liability between sub-funds)

10 Earlsfort Terrace

Dublin 2 D02 T380

Ireland

This document is important and requires your immediate attention. If you are in any doubt as to the action you should take, you should seek advice from your investment consultant or other professional advisors. This document has not been reviewed by the Central Bank of Ireland (the "Central Bank").

If you have sold or transferred all of your shares in Global X NASDAQ 100® Covered Call UCITS ETF (the "Fund"), please pass this document at once to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee as soon as possible.

Capitalised terms used herein shall bear the same meaning as defined in the prospectus of Global X ETFs ICAV (the "ICAV) dated 6 May 2021, as amended by addenda thereto dated 13 December 2021 and 13 May 2022 respectively, (the "Prospectus") and the supplement in respect of the Fund (the "Supplement"). Copies of the Prospectus and Supplement are available upon request during normal business hours from the registered office of the ICAV.

1 December 2022

RE:   Notification of amendments to the index methodology effective 15 December 2022 and other amendments

Dear Investors,

The ICAV is an open-ended investment vehicle with variable capital organised under the laws of Ireland and is authorised by the Central Bank pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011, as amended.  The Fund is a sub-fund of the ICAV.

This notice is to inform investors of the Fund of the following index methodology changes:

Index Methodology Changes:

The index methodology of the Index of the Fund will change as follows on 15 December 2022:

Previous methodology:

The Index each month measures the performance of a portfolio of the equity securities included in the NASDAQ-100® Index (the "Reference Index") while it also "writes" (or sells) a succession of one-month at-the-money covered call options on the securities in the Reference Index, which are held until one day prior to the expiration dates (i.e., generally the Thursday preceding the third Friday of the month) and are liquidated at a volume-weighted average price determined at the close.

Updated methodology:

The Index each month measures the performance of a portfolio of the equity securities included in the NASDAQ-100® Index (the "Reference Index") while it also "writes" (or sells) a succession of one-month at-the-money covered call options on the securities in the Reference Index, which are held until the expiration dates (i.e., generally the third Friday of the month) (the "Roll Date") and are liquidated at a time-weighted average price of the new call option during the two-hour period beginning at 11:30 EST on the Roll Date.

Full details of the Index methodology changes of the Index can be found at: 202211_Methodology_Change_for_the_Cboe_NASDAQ-100_BuyWrite_V2_UCITS_Index.pdf

Distributions

We would also like to take this opportunity to advise investors that the Supplement will be also updated to advise investors that as a consequence of the Distributing Classes distributing on a monthly basis there may be circumstances where dividend frequency of some, or all, of the constituents of the Index is less than the distribution frequency of the Distributing Classes. In these circumstances, distributions declared in respect of the Distributing Classes, on the basis of an indicative annual dividend yield of the Index constituents, may comprise net income (if any) of the Fund but may also be paid out of the capital of the Fund attributable to the Distributing Classes. Given this is the case, the disclosure contained in the Supplement will be clarified to reflect the potential for distributions to be paid out of capital in addition to net income.

The proposed changes outlined above necessitate that the Supplement be updated accordingly and these updates to the Supplement will take effect on, or around, 15 December 2022, subject to the approval of the Central Bank.

Should you have any questions relating to the changes detailed above, you should contact your local

agent, or (if none) Global X ETFs on +44 (0)20 4529 2551 or europe@globalxetfs.com, or alternatively you should contact your investment consultant, tax adviser and/or legal adviser as appropriate.

Yours faithfully,

_______________

For and on behalf of

Global X ETFs ICAV

Registered Office: as above

Registration Number: C435449

Directors: Feargal Dempsey, Mary Canning and Luis Berruga (USA)